This is the first in a series of posts that will review OHE’s contributions to advancing thought and stimulating innovative ideas in its three key research areas: financing and delivery of health care, HTA methods and processes, and the economics of the pharmaceutical and life sciences industries.
The August 2011 issue of Health Affairs featured four articles on how and why pricing for pharmaceuticals differs from one country to another. The OHE’s Prof Adrian Towse co-authored the lead article with Prof Patricia Danzon from the Wharton School and Dr Andrew Mulcahy of RAND.
Just published by OHE researchers is a comprehensive analysis of what policy measures are needed to counter the growing global problem of antimicrobial resistance. Their key findings are summarised in this blog post.
In October 2009, the OHE published research that compared access to orphan medicinal products (OMPs) in selected European countries. At the request of the UK Orphan Medicines Industry Group , OHE recently updated to May 2011 some of the data included in that research.
Most patients in middle and low income countries (MLICs) lack insurance coverage and so pay out of pocket for prescription medicines; pricing commensurate with income thus becomes critical to access to drugs. In this paper, the authors examine what determines the prices that manufacturers charge for originator and generic drugs across countries at all income levels.